Understanding how genetics affect treatment response in aggressive breast cancer among different racial groups
Assessing molecular predictors of triple negative breast cancer therapeutic response in Black, White, and Hispanic patients in a community healthcare system
This study is looking at how different biological factors affect the way Black, White, and Hispanic patients with triple negative breast cancer respond to treatments, so we can find better ways to help everyone get the most benefit from their care.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jackson Laboratory NIH-funded |
| Lab location | 1 site (Bar Harbor, United States) |
| Project ID | NIH-11065533 on NIH RePORTER |
What this research studies
This research investigates the biological factors that influence how different racial and ethnic groups respond to treatment for triple negative breast cancer (TNBC), particularly focusing on Black, White, and Hispanic patients. The study aims to identify molecular predictors, such as BRCA1/2 mutations and immune-related gene signatures, that can help determine which patients are more likely to benefit from specific therapies. By analyzing tumor samples and clinical outcomes, the research seeks to improve treatment strategies and outcomes for patients with TNBC. Patients may be asked to provide biospecimens and participate in assessments related to their cancer treatment and response.
Who could benefit from this research
Good fit: Ideal candidates for this research include Black, White, and Hispanic women diagnosed with triple negative breast cancer.
Not a fit: Patients with non-triple negative breast cancer or those outside the specified racial and ethnic groups may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with triple negative breast cancer.
How similar studies have performed: Previous research has shown promising results in identifying molecular predictors of treatment response in breast cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Bar Harbor, United States
- Jackson Laboratory — Bar Harbor, United States (Active)
Researchers
- Principal investigator: Menghi, Francesca — Jackson Laboratory
- Study coordinator: Menghi, Francesca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.